Phamrmacoligical Therapies for COVID-19: A Comprehensive Review from 2022 Updated Nih, IDSA and ICMR Guidelines
Ab Ahad Wani, Kar Tahir Ashraf, Malik latief Ab, Jawhar Ul Islam, Aamir Shafi, Wani Mubashir, Aleena Ahmad, Khan Azra, Dawood Ahmad, Nayarah Altaf, Shahid Ahmad
Asian Journal of Medicine and Health · pp. 6–13 · Published 21 Mar 2022
10.9734/ajmah/2022/v20i330444Abstract
Coronavirus disease 2019 (COVID-19) has had catestrophic results on the world’s economy and demographics leading to more than 4 million fatalities.This has been the most devastating world crisis after the 1918 pandemic which was caused by influenza. The main concerns regarding the disease have been lack of specific antiviral therapies. Results from recent trials have given some hope and promising results for the treatment of COVID-19 especially Molnupiravir, Monoclonal antibodies and Janus kinase inhibitors. This review article gives a comprehensive update on various pharmacological therapies in the light of recently published standard treatment guidelines based on large clinical trials for the treatment of COVID-19.
Cited by 1
R. Parameswari, R. Babujanarthanam, Thalaivarisai Balasundaram Sridharan · Materials Today: Proceedings · 2023
Related research
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Assessment of Anxiety in Healthcare Providers Working in ICU during COVID-19 Pandemics — shares topic coverage
- Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
- Elevated Levels of Lactate Dehydrogenase Predicts Poor Outcomes for Patients with COVID-19: A Review — shares topic coverage
- Addressing the Challenges of Containing Covid-19 Spread in a Rural, Poor Area in India: A Case Study — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
1
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.